[HTML] nih.gov

[HTML][HTML] Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination …

C Carbone, G Piro, A Agostini, P Delfino… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Complex tumor and immune microenvironment render pancreatic ductal
adenocarcinoma (PDAC) resistant to immune checkpoint inhibitors (ICIs). Therefore, a …
被引用次数：36 相关文章 所有 15 个版本
[HTML] nih.gov

[HTML][HTML] Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic …

J Ye, BN Mills, SS Qin, J Garrett-Larsen… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Stereotactic body radiotherapy (SBRT) has been increasingly used as adjuvant
therapy in pancreatic ductal adenocarcinoma (PDAC), and induces immunogenic cell death …
被引用次数：25 相关文章 所有 6 个版本
[HTML] nature.comFull View

[HTML][HTML] CD14/TLR4 priming potentially recalibrates and exerts anti-tumor efficacy in tumor associated macrophages in a mouse model of pancreatic carcinoma

H Prakash, V Nadella, S Singh… - Scientific reports, 2016 - nature.com
Pancreatic cancer is the fourth major cause of cancer related deaths in the world and 5 year
survival is below 5%. Among various tumor directed therapies, stimulation of Toll-like …
被引用次数：35 相关文章 所有 9 个版本

Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

CWF van Eijck, H El Haddaoui, S Kucukcelebi… - Clinical Cancer …, 2024 - AACR
Purpose: Amid the need for new approaches to improve survival in pancreatic ductal
adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a …
被引用次数：2 相关文章 所有 3 个版本
[HTML] nature.comFull View

[HTML][HTML] Targeting chemokines/chemokine receptors: A promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma

R Gong, H Ren - Signal Transduction and Targeted Therapy, 2020 - nature.com
In recent study published on Nature Medicine, Bockorny et al. 1 performed a single-arm
phase IIa trial (COMBAT study, NCT02826486) to evaluate safety, efficacy …
被引用次数：14 相关文章 所有 5 个版本
[HTML] springer.comFull View

[HTML][HTML] Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other …

SR Mullins, JP Vasilakos, K Deschler, I Grigsby… - … for immunotherapy of …, 2019 - Springer
Background Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor
regression in some cancer patients. However, in patients with immunologically “cold” …
被引用次数：147 相关文章 所有 14 个版本
[HTML] jci.org

[HTML][HTML] IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma

AB Blair, J Kleponis, DL Thomas… - The Journal of …, 2019 - Am Soc Clin Investig
Pancreatic ductal adenocarcinoma (PDAC) represents an immune quiescent tumor that is
resistant to immune checkpoint inhibitors. Previously, our group has shown that a GM-CSF …
被引用次数：61 相关文章 所有 8 个版本
[HTML] nih.gov

Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance

T Heumann, N Azad - Cancer and Metastasis Reviews, 2021 - Springer
To date, the use of immune checkpoint inhibitors has proven largely ineffective in patients
with advanced pancreatic ductal adenocarcinoma. A combination of low tumor antigenicity …
被引用次数：13 相关文章 所有 7 个版本
[HTML] nih.gov

[HTML][HTML] Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic …

X Zhang, M Lao, J Xu, Y Duan, H Yang… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Methods Tumor necrosis factor receptor 2 (TNFR2) was analyzed via immunohistochemistry,
immunofluorescence, western blotting, and ELISAs. The in vitro mechanism that TNFR2 …
被引用次数：35 相关文章 所有 8 个版本
[HTML] springer.comFull View

[HTML][HTML] Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review

HB Li, ZH Yang, QQ Guo - Cell Communication and Signaling, 2021 - Springer
Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate
among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common …
被引用次数：36 相关文章 所有 12 个版本